SciELO - Scientific Electronic Library Online

 
vol.96 issue3Merkel cell carcinoma: A case with atypical location and sizeHair transplant in lichen planopilaris author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO

Share


Revista argentina de dermatología

On-line version ISSN 1851-300X

Abstract

JAQUE, A; ORTIZ, E; VIAL, V  and  VERA-KELLET, C. Severe atopic dermatitis with generalized molluscum contagiosum and their response to intravenous immunoglobulin: Case report and literature review. Rev. argent. dermatol. [online]. 2015, vol.96, n.3, pp.14-21. ISSN 1851-300X.

Background: atopic dermatitis (AD) is a chronic inflammatory skin disease that affects between 1 to 3% of adults. Case: we report a case of a 23-years old woman with history of asthma, allergic rhinitis and severe atopic dermatitis (SAD), with poor previous response to four systemic treatments. She consulted due to exacerbation of her AD and a four month-course of progressive papular lesions, compatible with molluscum contagiosum. Laboratory evaluation showed hypereosinophilia and IgE levels > 20.000. Because of the severity of the clinical condition and taking in consideration the patient´s immunosupression state, intravenous immunoglobulin (IVIg) 0,4 mg/kg/day was started for five days and three cycles, with good response of her cutaneous lesions. Discussion: the standard therapies for AD are mainly focused on symptomatic relief and its clinical efficacy is often insufficient. The treatment with IVIg is effective in some dermatological autoinflammatory diseases and there are few reports in this matter, especially in children. Other treatments available for these cases are interferon-gamma and omalizumab, but the actual evidence is insufficient and it is required more prospective studies to support their use.

Keywords : Severe atopic dermatitis; Treatment; Intravenous immunoglobulin; Omalizumab; Interferon-gamma.

        · abstract in Spanish     · text in Spanish

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License